Integrative Biomarker Panel for Improved Lung Cancer Diagnosis Using Plasma microRNAs and Sputum Bacterial DNA DOI Creative Commons

Pushpa Dhilipkannah,

Ashutosh Sachdeva, Van K. Holden

и другие.

Current Oncology, Год журнала: 2024, Номер 31(10), С. 5949 - 5959

Опубликована: Окт. 2, 2024

This study aimed to evaluate if integrating diverse molecular biomarkers in plasma and sputum could improve the diagnosis of lung cancer. The analyzed miRNAs bacterial DNA from 58 cancer patients 62 cancer-free smokers using droplet digital PCR. individual miRNA had sensitivities 62–71% specificities 61–79% for diagnosing A panel or produced 79–85% 74–82%. An integromic signature consisting two three a higher sensitivity (87%) specificity (89%) compared biomarkers. signature’s diagnostic value was confirmed validation cohort 56 59 controls, independent tumor stage, histological type, demographic factors. Integrating

Язык: Английский

Tumor‐associated exosomes in cancer progression and therapeutic targets DOI Creative Commons
Xiaomin Liu, Fan Wu, Wei Pan

и другие.

MedComm, Год журнала: 2024, Номер 5(9)

Опубликована: Сен. 1, 2024

Exosomes are small membrane vesicles that released by cells into the extracellular environment. Tumor-associated exosomes (TAEs) play a significant role in cancer progression mediating intercellular communication and contributing to various hallmarks of cancer. These carry cargo proteins, lipids, nucleic acids, other biomolecules can be transferred recipient cells, modifying their behavior promoting tumor growth, angiogenesis, immune modulation, drug resistance. Several potential therapeutic targets within TAEs have been identified, including oncogenic miRNAs, tumor-associated antigens, checkpoint resistance tissue factor. In this review, we will systematically summarize biogenesis, composition, function highlight targets. Considering complexity exosome-mediated signaling pleiotropic effects exosome cargoes has challenge developing effective strategies. Further research is needed fully understand develop therapies target them. particular, development strategies block release, cargo, inhibit uptake, modulate content could provide novel approaches treatment.

Язык: Английский

Процитировано

2

Identification of a Plasma Exosomal lncRNA‐ and circRNA‐Based ceRNA Regulatory Network in Patients With Lung Adenocarcinoma DOI Creative Commons
Wangyu Zhu, Huafeng Zhang, L.J. Tang

и другие.

The Clinical Respiratory Journal, Год журнала: 2024, Номер 18(10)

Опубликована: Окт. 1, 2024

ABSTRACT Background Exosomes have been established to be enriched with various long noncoding RNAs (lncRNAs) and circular (circRNAs) that exert biological effects. However, the lncRNA‐ circRNA‐mediated coexpression competing endogenous RNA (ceRNA) regulatory network in exosomes derived from plasma of patients lung adenocarcinoma (LUAD) remains elusive. Methods Results This study enrolled nine three healthy individuals, differential expression messenger (mRNAs), lncRNAs, circRNAs was detected using microarray analysis, while microRNAs (miRNAs) were through sequencing. Additionally, bioinformatics algorithms applied evaluate lncRNA–miRNA–mRNAs/circRNA–miRNA–mRNA network. Differentially expressed cicRNAs identified via quantitative reverse transcription polymerase chain reaction (RT‐qPCR). A total 1016 1396 circRNAs, 45 miRNAs, 699 mRNAs differentially LUAD compared controls. Among them, 881 lncRNAs upregulated 135 downregulated, 916 480 miRNAs none 591 108 downregulated ( p ≤ 0.05, fold change ≥ 2). Gene Ontology (GO) analysis Kyoto Encyclopedia Genes Genomes (KEGG) pathway revealed functions RNAs. Meanwhile, networks displayed relationship between dysregulated Finally, RT‐qPCR validated circ‐0033861, circ‐0043273, circ‐0011959 exosome controls = 0.0327, 0.0002, 0.0437, respectively). Conclusion proposed a newly discovered ncRNA–miRNA–mRNA/circRNA–miRNA–mRNA ceRNA circulating up‐regulated LUAD, offering valuable insights for exploring potential function exosomal identifying biomarkers LUAD.

Язык: Английский

Процитировано

2

Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC DOI Open Access
Vivi Bafiti, Eleni Thanou, Sotiris Ouzounis

и другие.

Cancers, Год журнала: 2024, Номер 16(22), С. 3729 - 3729

Опубликована: Ноя. 5, 2024

Lung cancer, the second most prevalent cancer globally, poses significant challenges in early detection and prognostic assessment. Despite advancements targeted therapies immunotherapy, timely identification of relapse remains elusive. Blood-based liquid biopsy biomarkers, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), (ctDNA), circulating-free RNAs (cfRNAs), extracellular vesicles (EVs)/exosomes, offer promise for non-invasive monitoring.

Язык: Английский

Процитировано

2

MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements DOI Creative Commons
Isabel Legáz, Víctor Jiménez-Coll,

Rosana González-López

и другие.

Biomedicines, Год журнала: 2024, Номер 12(1), С. 116 - 116

Опубликована: Янв. 5, 2024

Allograft rejection is a widespread complication in allograft recipients with chronic kidney disease. Undertreatment of subclinical and clinical later post-transplant problems are caused by an imperfect understanding the mechanisms at play lack adequate diagnostic tools. Many different biomarkers have been analyzed proposed to detect monitor these crucial events transplant outcomes. In this sense, microRNAs may help diagnose or tolerance indicate appropriate treatment, especially patients rejection. As key epigenetic regulators physiological homeostasis, therapeutic potential However, more evidence validation indispensable before ready for prime time.

Язык: Английский

Процитировано

1

Downregulation of hsa_circTLK1 represses non-small cell lung cancer progression by regulating miR-876-3p/SRSF7 axis DOI Creative Commons

Xinzhe Dong,

Hui Tian, Peng Ren

и другие.

Heliyon, Год журнала: 2024, Номер 10(11), С. e31972 - e31972

Опубликована: Май 25, 2024

Backgrounds: This study clarified the expression of cicrTLK1 in non-small cell lung cancer (NSCLC) and explored its role growth, metastasis immune escape, providing a potential molecular target theoretical basis for NSCLC immunotherapy.MethodsThe levels circTLK1, miR-876-3p SRSF7 were determined by RT-qPCR assay. The localization circTLK1 cells was FISH EdU plate clone formation assay applied to explore proliferation. Wound healing test Transwell measure migration invasion ability. Cell apoptosis rate detected FCM Western blotting adopted protein SRSF7. Dual-luciferase reporter gene assess interaction between ability cirTLK1 regulate tumor vivo examined transplantation experiments nude mice.ResultsThe relative increased lines. Knockdown prohibited proliferation, migration, invasion, promoted rate, but inhibitor reversed effects knockdown. In addition, silencing overtly restrained growth transplanted tumors vivo, inhibited escape. interacted with miR-876-3p, concluded be miR-876-3p.ConclusionIn this study, we researched inhibitory effect circTLK1knockdown on progression further elucidated regulatory mechanism circTLK1/miR876-3p/SRSF71 axis.

Язык: Английский

Процитировано

0

Integrative Biomarker Panel for Improved Lung Cancer Diagnosis Using Plasma microRNAs and Sputum Bacterial DNA DOI Creative Commons

Pushpa Dhilipkannah,

Ashutosh Sachdeva, Van K. Holden

и другие.

Current Oncology, Год журнала: 2024, Номер 31(10), С. 5949 - 5959

Опубликована: Окт. 2, 2024

This study aimed to evaluate if integrating diverse molecular biomarkers in plasma and sputum could improve the diagnosis of lung cancer. The analyzed miRNAs bacterial DNA from 58 cancer patients 62 cancer-free smokers using droplet digital PCR. individual miRNA had sensitivities 62–71% specificities 61–79% for diagnosing A panel or produced 79–85% 74–82%. An integromic signature consisting two three a higher sensitivity (87%) specificity (89%) compared biomarkers. signature’s diagnostic value was confirmed validation cohort 56 59 controls, independent tumor stage, histological type, demographic factors. Integrating

Язык: Английский

Процитировано

0